Beyond glycemic control: differential effects of empagliflozin and sitagliptin on insulin sensitivity and a shared increase in adropin in type 2 diabetes
Otbah Salim Taha, Golnaz Azami, Lotfollah Saed, Mohammad Saeed Hakhamaneshi, Heresh Moridi · 2026
Read Beyond glycemic control: differential effects of empagliflozin and sitagliptin on insulin sensitivity and a shared increase in adropin in type 2 diabetes by Otbah Salim Taha, Golnaz Azami, Lotfollah Saed, Mohammad Saeed Hakhamaneshi, Heresh Moridi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13418427.txt.
Description
Otbah Salim Taha and co-authors report a 2026 trial that compares two added drugs for type 2 diabetes. Adults whose blood sugar stayed high on metformin alone got either empagliflozin or sitagliptin for twelve weeks. The team tracked a blood protein called adropin, insulin response, sugar control, fats, and swelling markers.
Both drugs raised adropin by a like amount. Both also cut insulin resistance and long term sugar levels, with larger drops on empagliflozin. That drug also cut fasting insulin and blood fats more. A swelling marker fell in both groups. The authors say the two drugs share some gains but differ in how they shift metabolism.
Catalog record
| CREATOR | Otbah Salim Taha, Golnaz Azami, Lotfollah Saed, Mohammad Saeed Hakhamaneshi, Heresh Moridi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 94 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |